Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: Results of the vesnarinone trial withdrawal substudy

Journal of Cardiac Failure

Volumn 5, Issue 3, 1999, Pages 195-200

  Soran, Ozlem ^a   Young, James D ^b   Holubkov, Richard ^a   Loftus, Susan ^a   Bourge, Robert ^c   Carson, Peter ^d   Jaski, Brian ^e   White, B G ^f   Feldman, Arthur M ^a,g  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Sharpe Memorial Hospital   (United States)

^f Cardiovascular Genetics Research Clinic   (United States)

^g S 572 Scaife Hall ^*  (United States)

Author keywords

Congestive heart failure; Inotropic agents; Survival

Indexed keywords

PIPERANOMETOZINE;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; INOTROPISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0032882372     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(99)90003-9     Document Type: Article

References (16)

1. LeJemtel TH, Sonnenblick EH: Should the failing heart be stimulated? N Engl J Med 1984;310:1384-5
2. Cohn JN: Inotropic therapy for heart failure: paradise postponed. N Engl J Med 1989;320:729-31
3. Cody RJ: Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? Introduction. J Am Coll Cardiol 1988;12:559-61
4. The Captopril-Digoxin Multicenter Research Group: Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988; 259:539-44
5. Fleg JL, Gottlieb SH, Lakatta EG: Is digoxin really important in treatment of compensated heart failure? A placebocontrolled crossover study in patients with sinus rhythm. Am J Med 1982;73:244-50
6. Pugh SE, White NJ, Aronson JK, Grahame-Smith DG, Bloomfield JG: Clinical, haemodynamic, and pharmacological effects of withdrawal and reintroduction of digoxin in patients with heart failure in sinus rhythm after long-term treatment. Br Heart J 1989;61: 529-39
7. Jaeschke R, Oxman AD, Guyatt GH: To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and metaanalysis. Am J Med 1990;88:279-86
8. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK: Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. RADIANCE Study. N Engl J Med 1993;329:1-7
9. Feldman AM: Pharmacologic properties and clinical evaluation of the new inotropic agent OPC-8212 (vesnarinone). Cardiovasc Drug Rev 1993;11:1-11
10. Kass DA, Van Anden E, Becker LC, Kasper EK, White WB, Feldman AM: Dose-dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy. Am J Physiol 1996;78:652-6
11. Gorcsan J, Murali S, Mandarino WA, Feldman AM: Inotropic effects of vesnarinone in severe heart failure: results of the VEST ventricular function substudy. Circulation 1998;98:I579-80
12. Cohn JN, Goldstein S, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F, MeMets DL, White BG, for the Vesnarinone Trial Investigators: Dose-dependent mortality increase from vesnarinone in severe heart failure: the Vesnarinone Trial results. N Engl J Med 1998;339:1810-6
13. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG, for the Vesnarinone Study Group: Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 329:149-55
14. Hosokawa T, Mori T, Fujiki H, Kinoshita S, Takemoto K, Imaizumi T, Noda T, Ohura M, Tominaga M, Yabuuchi Y: Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action. Heart Vessels 1992;7:66-75
15. Takeya K, Yajima M, Kobayashi-Ando S, Ando H: Positive inotropic effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212) and mechanism of action in guinea pig ventricular myocardium. Arzneimittelforschung 1984;34: 364-70
16. Schwartz A, Wallick ET, Lee SW, Wang T, Hosakawa T, Whitmer KR, Matlib MA: Studies on the mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212), a new positive inotropic drug. Enzyme activities and Ca2+ transport processes of sarcolemma and intracellular organelles. Arzneimittelforschung 1984;34:384-9